Previous Article | Next Article ![]()
Journal of Virology, September 1998, p. 7125-7136, Vol. 72, No. 9
Centre de Recherche en Infectiologie, Centre
Hospitalier Universitaire de Québec, Pavillon CHUL, and
Département de Biologie médicale, Faculté de
Médecine, Université Laval, Ste-Foy, Québec,
Canada G1V 4G2
Received 17 February 1998/Accepted 26 May 1998
The ICAM-1/LFA-1 interaction has been clearly demonstrated to play
an active role in syncytium formation induced by human immunodeficiency
virus type 1 (HIV-1). Since it is known that a high-affinity state of
LFA-1 for ICAM-1 can be induced through conformational change, such a
high-affinity state may also contribute to the process of syncytium
formation. In this study, we have investigated the involvement of the
conformational status of LFA-1 in HIV-1-dependent syncytium formation
by using the anti-LFA-1 antibody NKI-L16, which is known to activate
the high-affinity state. Initial visual observations by light
microscopy indeed suggested that the addition of the NKI-L16 antibody
led to bigger and more numerous syncytia when different cell lines were
tested. To further analyze this NKI-L16-dependent increment of
syncytium formation in a quantitative assay, a new luciferase-based
assay was developed by using a T-cell line containing an HIV-1 long terminal repeat (LTR)-driven luciferase construct (1G5) in
coincubation with an HIV-1-positive cell line (J1.1). Upon fusion, the
viral Tat protein could diffuse to the 1G5 cells, leading to a
transcriptional increase of the HIV-1 LTR-driven luciferase gene.
Initial evaluation of this assay showed a good correlation between the
level of syncytium formation determined by microscopic observation and
the level of measured luciferase activity. In addition, this assay
showed a greater induction of enzymatic activity correlating with
syncytium formation in comparison to a similar incubation with the
HeLa-CD4-LTR-
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Modulation of Human Immunodeficiency Virus Type 1-Induced
Syncytium Formation by the Conformational State of LFA-1 Determined
by a New Luciferase-Based Syncytium Quantitative Assay
-gal indicator cell line. By using this test,
NKI-L16 treatment of 1G5/J1.1 cells led to a three- to sevenfold
increase in HIV-1 LTR-driven luciferase activity. The
syncytium-dependent luciferase activity in NKI-L16-treated cells could
be blocked by classical syncytium inhibitors such as soluble CD4,
anti-CD4, and anti-gp120 antibodies. Inhibition could also be observed
with specific blocking agents for the chemokine receptor CXCR4, as well
as with soluble ICAM-1, anti-LFA-1, anti-ICAM-1, and
anti-ICAM-2 blocking antibodies, indicating the requirement for the
LFA-1/ICAM interaction. Treatment of peripheral blood
mononuclear cells with NKI-L16 resulted in a higher level of syncytium
formation in the presence of the cell line J1.1. Conversely, when PBMCs
were infected with two different syncytium-inducing HIV-1
primary isolates, coincubation with NKI-L16-pretreated 1G5 cells
led to higher levels of luciferase activity for both virus isolates.
Our results therefore show for the first time a direct role for the
LFA-1 high-affinity state in virus-mediated syncytium
formation. Based on the demonstration that an increase in ICAM-1
binding is induced by T-cell activation, these data suggest an in vivo
involvement of the high-affinity state of LFA-1 in HIV-1-induced
syncytium formation. Moreover, syncytia might preferentially occur in
lymph nodes, since this microenvironment harbors a high proportion of
activated T cells.
*
Corresponding author. Mailing address: Unité
d'ImmunoRétrovirologie Humaine, Centre de Recherche en
Infectiologie, RC709, Centre Hospitalier Universitaire de
Québec, Pavillon CHUL, 2705 blvd. Laurier, Ste-Foy, Québec,
Canada G1V 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail:
michel.j.tremblay{at}crchul.ulaval.ca.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|